Navigation Links
Mayo Clinic researchers: Insulin-boosting medication does not impair ability to survive heart attack
Date:11/5/2007

ORLANDO, Fla. -- Mayo Clinic researchers helped clarify a growing concern about the link between diabetes mellitus treatments and heart attack with the first large, population-based study showing that a group of common medications does not reduce diabetic patients heart attack survival rates. These results were presented today at the American Heart Associations Scientific Sessions 2007 in Orlando, Fla.

The drugs studied are called sulfonylureas and include several commonly used pills to increase insulin release to lower blood sugar. Second-generation sulfonylureas -- known collectively as SU2 -- include glimepiride (Amaryl), glipizide (Glucotrol, Glucotrol XL), and glyburide (DiaBeta, Micronase, Glynase).(1)

Significance of the Mayo Clinic Study

The prevalence of diabetes mellitus is growing rapidly, and physicians need evidence for their treatment recommendations. Worldwide, the number of diabetics is projected to more than double in three decades, from 171 million in 2000 to 366 million in 2030.(2) Many patients with diabetes are at increased risk for heart failure. This complicates their treatment, and has raised concern in recent years among some physicians that SU2s may impair the hearts ability to withstand stress, thus reducing patients ability to survive heart attacks, says Veronique Roger, M.D., M.P.H., the Mayo cardiologist and epidemiologist who led the study.

The Mayo study is the first to use a broad population of community members to extract information about the impact of various diabetes treatments on patients health after heart attack. The Mayo group evaluated the outcome of heart attack in two groups: people who had diabetes and those who did not. Group members were similar in terms of age, gender and lifestyle habits such as smoking. In the diabetes group, researchers tracked patient outcome after heart attack in patients taking three different treatment approaches to lowering blood sugar: SU2 drugs, insulin, diet.

These data do not support the concern among some physicians of an adverse impact of SU2 on survival after a heart attack, Dr. Roger says. These results provide clinical guidance for physicians faced with managing a growing number of diabetic patients. Our study is also important because it underscores the potential role of community-based studies for helping provide evidence to clarify treatment strategies and improve care of patients.

About the Study

Using a specialized patient-records database maintained since 1936, researchers identified all heart attacks that occurred in Olmsted County, Minn., where Mayo Clinic is based, between 1979 and 2002. They identified 2,732 heart attack patients, with an average age of 70; 56 percent were women. Of the heart attack group, 486 (18 percent) also had diabetes mellitus. The diabetes patients were split into three groups and treated with SU2 drugs, insulin, or diet alone.


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Radiologists encouraged to look beyond cancer for clinically unseen diseases
3. Clinical depression linked to abnormal emotional brain circuits
4. Preclinical study suggests organ-transplant drug may aid in lupus fight
5. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
6. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
7. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
8. MinuteClinic Becomes Participating Provider with Assurant Health
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Acupuncturists Relocation Tightens Relationship With Fertility Clinic
11. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Only two ... International Luxury Travel Market (ILTM) show in Cannes (France), XO Private has initiated a ... tome, the 420-page book measures almost a metre across when open, weighs in at ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. ... announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as ... beginning April 10. Dr. Bell comes to Liberty from the Ohio University Heritage ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... hearing disabilities, it is so critically important that we all are aware of ... is why Mediaplanet is proud to announce the launch of its newest edition ...
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... With ... Final Cut Pro X . Users have total control over position, rotation, distortion, edge ... more all within Final Cut Pro X. , With ProGlass Prism users are given ...
(Date:2/24/2017)... ... 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) announces ... See” body image mannequin art competition. Selected from 15 submissions from around the nation, ... at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... HARRISBURG, Pa. , Feb. 24, 2017 ... Secretary of Drug and Alcohol Programs Jennifer Smith ... role in providing training for and using naloxone, a ... Mark McCullough , a recovery specialist and overdose ... naloxone by EMS providers. "A significant part ...
(Date:2/24/2017)... 2017 The U.S. Food and Drug ... Kit, performed on the Pheno System. This is ... bloodstream infections and provide information about which antibiotics ... sensitivity). The test also reduces the amount of ... which can guide antibiotic treatment recommendations more quickly. ...
(Date:2/24/2017)... Feb. 23, 2017  Directors from Pharma To Market Pty Ltd ... joined forces, resulting in the founding of Pharma To Market Pte ... To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... the Singapore based entity. Joelle brings with ...
Breaking Medicine Technology: